Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Link Between Vitamin D and Lymphoma Survival

Analysis of patients in SWOG and LYSA trials

Serum vitamin D levels may be a potentially modifiable factor associated with survival in follicular lymphoma (FL), according to an analysis of two cohort studies of patients with previously untreated FL.

Using baseline serum samples of 25-hydroxyvitamin D, investigators analyzed the adjusted progression-free survival (PFS) hazard ratio (HR) and overall survival HR for patients in SWOG and Lymphoma Study Association (LYSA) trials. In patients who were vitamin D deficient (<20 ng/mL in SWOG or <10 ng/mL in LYSA), the following PFS and overall survival HRs were as follows:

PFS

Survival

SWOG

1.97

4.16

LYSA

1.50

1.92

Citation: Kelly JL, Salles G, Goldman B, et al. Low serum vitamin D levels are associated with inferior survival in follicular lymphoma: a prospective evaluation in SWOG and LYSA studies. J Clin Oncol. 2015. pii: JCO.2014.57.5092.

This Week's Must Reads

Broad opioid legislation advances in Congress, Senate floor debate, Sept. 17, 2018

Early supportive care cuts costs related to curative treatment, Koprowski CD et al. 2018 ASCO Quality Care Symposium, Abstract 142

Employee deductibles outstrip wages, Kaiser Family Foundation, 2018 Employer Health Benefits

The financial burden of metastatic breast cancer, Wheeler SB et al. Quality Care Symposium, Abstract 32

Must Reads in Lymphoma & Plasma Cell Disorders

Long-term data on chemo-free approach in advanced indolent lymphoma, Lockmer S et al. J Clin Oncol. 2018 Oct 4:JCO1800262. doi: 10.1200/JCO.18.00262

Race and pruritus create cancer risk picture, Kwatra SG et al. J Am Acad Dermatol. 2018 Sep 11. doi: 10.1016/j.jaad.2018.08.044.

Adding Bv improved survival for some Hodgkin patients, Evens AM et al. J Clin Oncol. 2018 Sep 4. doi: 10.1200/JCO.2018.79.0139.

First-line chemo-free MCL combo is durable, Ruan J et al. Blood. 2018 Sep 4. doi: 10.1182/blood-2018-07-859769.

Long-term ibrutinib data in older patients, Barr PM et al. Haematologica. 2018;103(9):1502-10